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Abstract
Objective Amide proton transfer (APT) weighted chemical exchange saturation transfer (CEST) imaging is increasingly used 
to investigate high-grade, enhancing brain tumours. Non-enhancing glioma is currently less studied, but shows heterogeneous 
pathophysiology with subtypes having equally poor prognosis as enhancing glioma. Here, we investigate the use of CEST 
MRI to best differentiate non-enhancing glioma from healthy tissue and image tumour heterogeneity.
Materials & Methods A 3D pulsed CEST sequence was applied at 3 Tesla with whole tumour coverage and 31 off-resonance 
frequencies (+6 to -6 ppm) in 18 patients with non-enhancing glioma. Magnetisation transfer ratio asymmetry (MTRasym) 
and Lorentzian difference (LD) maps at 3.5 ppm were compared for differentiation of tumour versus normal appearing white 
matter. Heterogeneity was mapped by calculating volume percentages of the tumour showing hyperintense APT-weighted 
signal.
Results LDamide gave greater effect sizes than MTRasym to differentiate non-enhancing glioma from normal appearing 
white matter. On average, 17.9 % ± 13.3 % (min–max: 2.4 %–54.5 %) of the tumour volume showed hyperintense LDamide 
in non-enhancing glioma.
Conclusion This works illustrates the need for whole tumour coverage to investigate heterogeneity in increased APT-weighted 
CEST signal in non-enhancing glioma. Future work should investigate whether targeting hyperintense LDamide regions for 
biopsies improves diagnosis of non-enhancing glioma.
Keywords Non-enhancing glioma · CEST · APT · NOE
Introduction
Chemical exchange saturation transfer (CEST) is a technique 
to create magnetic resonance imaging (MRI) contrasts by 
selective targeting of labile protons in endogenous and 
mobile proteins. An emerging clinical application of CEST 
imaging is the assessment of glioma via amide proton trans-
fer (APT) weighted CEST, which recently has shown prom-
ise for glioma grading [1, 2] and the differentiation between 
pseudoprogression and radiation necrosis [3].
Although patients with non-enhancing gliomas are often 
included in studies investigating APT-weighted CEST MRI, 
the main aim is often differentiation of glioma grade based 
on the classic histological classification of low to high-grade 
tumours, where high-grade tumours often show enhance-
ment and form the majority of the studied population. The 
current body of literature indicates that lower grade glio-
mas are mostly isointense on amide proton transfer (APT)-
weighted imaging, with potentially some areas of hyperin-
tensity and that high-grade gliomas, i.e. glioblastomas, show 
increased APT-weighted CEST signal [1, 4]. However, in 
non-enhancing glioma, APT-weighted CEST could have an 
important role as these tumours can become very large and, 
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like glioblastomas, have spatially varying pathophysiology 
and underlying molecular signatures [5]. The latter is of par-
ticular importance in light of the recently updated molecular 
classification of tumours as published by the World Health 
Organisation [6]. Whereas non-enhancing glioma used to 
be classified based on histology only, now two molecular 
parameters (IDH mutation and 1p/19q codeletion) are of 
interest that lead to three distinct classes of non-enhancing 
glioma [7]. These three classes differ widely in progno-
sis, ranging from a median overall survival of more than 
10 years to just over 1 year, similar to enhancing glioblas-
toma (grade IV). Moreover, each of these classes warrants 
a different treatment regime, which stresses the need for 
accurate diagnosis.
Additionally, although the number of CEST research 
studies including multi-slice image acquisition schemes is 
increasing, previous investigations including non-enhancing 
glioma often use single-slice CEST acquisitions [4, 8, 9]. 
Because this excludes investigation of the whole tumour 
volume, care needs to be taken when interpreting the above 
results found about APT-weighted CEST signal in non-
enhancing glioma. However, combining CEST preparations 
with a rapid 3D read-out has previously been shown to allow 
for the collection of multiple saturation offsets whilst cov-
ering the whole tumour volume in clinically feasible scan 
times [10, 11].
Here we use a 3D pulsed CEST sequence to explore 
APT-weighted signal in the whole tumour, specifically for 
non-enhancing glioma. We compare amide-weighted mag-
netisation transfer ratio asymmetry  (MTRasym) and Lorent-
zian difference (LD) contrasts, CEST metrics widely used 
in the current literature. The former is commonly applied 
and is valued for its relative simplicity as it, in its essence, 
only requires measurement of the CEST effect when apply-
ing a  B1 saturation pulse at two off resonance frequency 
shifts (3.5 ppm and − 3.5 ppm) in addition to a separate 
acquisition of multiple off-sets for  B0-correction. The latter 
requires covering multiple off-resonance frequencies via the 
acquisiton of a full Z-spectrum to do Lorentzian fitting of the 
CEST signal. This analysis allows for separate investigation 
of signal contributions from amide protons at 3.5 ppm and 
nuclear Overhauser enhancement (NOE) at – 3.5 ppm. Note 
that in CEST experiments NOE contributes signal between 
− 1 and − 5 ppm, where aliphatic protons in mobile mac-
romolecules are saturated. Via relayed-NOE this saturation 
is transferred to amide protons within the same molecule 
which will exchange with the free water pool [12]. Recently, 
NOE-weighted CEST signal has been shown to be correlated 
with prognosis [13, 14] and grading [15] of high-grade gli-
oma. Therefore, we additionally investigate whether NOE-
weighted CEST is of interest for non-enhancing glioma.
Materials and methods
All images were acquired on a 3 T MRI scanner equipped 
with a 32-channel head coil (Discovery MR750, General 
Electric, Chicago, USA). All experiments were conducted 
in compliance with the declaration of Helsinki and under 
approval of the institutional ethics committee of the Eras-
mus MC (Rotterdam, NL), which is one out of 18 accred-
ited medical research ethics committees in the Netherlands. 
Image analysis and statistical analysis were done with in-
house written Matlab scripts (R2015b, The MathWorks, 
Natick, USA) and the freely available FMRIB Software 
Library (FSL 5.0.9, Oxford, UK).
Patient information
Eighteen patients with newly diagnosed presumed low-grade 
glioma were recruited between March 2017 and March 2019. 
Patients were recruited as part of the Imaging Genomics 
study and were scanned at maximum 7 days before surgi-
cal resection or biopsy. Tumour samples were obtained and 
histopathologically examined by neuropathologists. Molecu-
lar classification of the 1p/19q co-deletion and IDH muta-
tion status was performed as part of the diagnostic routine 
by molecular biologists  with  targeted Next-Generation 
Sequencing (NGS) panels using an Ion Torrent Personal 
Genome Machine or Ion S5XL (Thermo Fisher Scientific). 
Patient characteristics can be seen in Table 1.
Image acquisition
CEST images were acquired with a 3D spoiled gradi-
ent echo with TR = 35.4 ms, TE = 6.9 ms, 12 slices, slice 
thickness = 5 mm, in-plane voxel size = 1.85 × 1.85  mm2, 
matrix = 128 × 128, acceleration factor = 4, similar to the 
pulsed CEST sequence used by Jones et al. [10]. Spectral-
spatial excitation pulses were used to avoid fat artefacts 
in images near the water peak. [16] A Gaussian satura-
tion pulse was played every TR with duration 20 ms (duty 
cycle 56.5%). Two CEST series were acquired at saturation 
powers  B1 = 2.3 and 4.0 µT, and each series consisting of 
31 frequency off-sets (± 6.0, ± 5.5, ± 5.0, ± 4.5, ± 4.0, ± 3.
75, ± 3.5, ± 3.25, ± 3.0, ± 2.5, ± 2.0, ± 1.5, ± 1.0, ± 0.75, ± 
0.5, ± 0.25, 0 ppm). Note that the saturation powers used 
are stated as the root mean square  B1 across the saturation 
pulse. Two images were acquired without saturation pulses 
to obtain the equilibrium magnetisation  (M0) for reference, 
bringing the total to 33 images acquired in ∼ 5 min. A  B1 
map was created by using a multi-slice 2D gradient echo 
sequence (TE = 12.8  ms, TR = 17  ms, flip angle = 10°) 
with voxel size and number of slices (1.85 × 1.85 × 5  mm3, 
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matrix = 128 × 128x12) matched to the CEST sequence. 
 T1-weighted (3D IR FSPGR, TE = 2. 1 ms, TR = 6.1 ms, 
voxel size = 1 × 1 × 0.5  mm3, field of view 256 mm, 352 
slices) and  T2-weighted FLAIR (3D spin echo read-out, 
voxel size = 1 × 1 × 1.6  mm3, matrix size = 224 × 224 × 264, 
TR/TE/TI = 6000 ms/112.9 ms/1893 ms) structural images 
were additionally acquired. Note that the 3D CEST acquisi-
tion was planned to cover the whole tumour, as indicated by 
the  T2-FLAIR hyperintense area.
Image analysis
Motion correction of the CEST image series was done by 
linear registration of each image within a series to the 6 ppm 
image and a cost function based on mutual information (mcf-
lirt, within FSL v5.0.9, Oxford, UK), after which linear reg-
istration was used to register the CEST images to the mag-
nitude of the  B1-map. Z-spectra were calculated by dividing 
the images acquired with off-resonance saturation pulses by 
the average of the two  M0 images. A Lorentzian curve was 
fitted to the Z-spectra using the data points with off-reso-
nance frequency shifts of ± 6 ppm and those from − 1.75 to 
1.75 ppm. This fit was first used for  B0-correction, by shift-
ing each spectrum by the frequency shift of the minimum 
value of the Lorentzian fit. Amide-weighted  MTRasym was 
calculated according to the methods described by Zhou et al. 
[17], using the  B0-corrected Z(3.5 ppm) and Z(− 3.5 ppm). 
Lorentzian Difference (LD) analysis was used to obtain maps 
for  LDamide at 3.5 ppm and  LDNOE at − 3.5 ppm [18–20]. The 
 MTRasym and LD contrasts were calculated for both  B1 satu-
ration powers acquired. Contrast-based  B1 correction was 
then carried out according to previously described methods, 
including the use of an artificial  B1 = 0 µT [21], resulting 
in voxel-wise  B0- &  B1-corrected  MTRasym,  LDamide, and 
 LDNOE. To avoid extrapolation in voxels with a  B1 below the 
nominal value of  B1 = 4.0 µT, in the remainder of the patient 
data the results are calculated for the images resulting from 
the  B1-correction with  B1 values of 2.5 and 3.8 µT.
Tumour regions of interest (ROI) were generated semi-
automatically by delineating the hyperintense area on the 
 T2-weighted FLAIR images using ITKSnap [22]. Note that 
no areas of necrosis were visually identifiable on the images 
acquired for the grade IV tumours (N = 6). The contralateral 
normal-appearing white matter (NAWM) ROI was generated 
by segmentation of white matter in the  T1-weighted images 
(fast, within FSL v5.0.9, Oxford, UK) and a linear registra-
tion of this segmentation to the FLAIR image. NAWM was 
determined by using the white matter contralateral to the 
tumour in all slices that also included the tumour segmen-
tation. Per patient, average tumour and NAWM  MTRasym, 
 LDamide, and  LDNOE were calculated.
To determine the extent of hyperintense amide-weighted 
CEST signal within the tumour per contrast and per patient, 
for each patient a threshold was determined as follows:
Tabel 1  Patient characteristics









P01 M 33 Oligodendroglioma – grade II Yes Yes 43.7 1.1 2.4
P02 F 57 Oligodendroglioma – grade II Yes Yes 177.6 41.2 23.2
P03 F 55 Oligodendroglioma – grade II Yes Yes 25.1 1.9 7.5
P04 M 35 Oligodendroglioma – grade II Yes Yes 227.1 57.0 25.1
P05 M 35 Oligodendroglioma – grade II Yes Yes 8.7 1.9 21.3
P06 M 31 Oligodendroglioma – grade II Yes Yes 16.9 1.1 6.4
P07 M 42 Oligodendroglioma – grade II Yes Yes 20.8 4.6 22.1
P08 M 39 Astrocytoma – grade II Yes No 80.0 28.1 35.1
P09 F 54 Astrocytoma – grade III Yes No 37.5 7.8 20.9
P10 F 46 Astrocytoma – grade III Yes No 62.6 21.0 33.6
P11 M 40 Astrocytoma – grade III Yes No 29.5 3.8 13.0
P12 F 24 Astrocytoma – grade III Yes No 79.7 4.1 5.2
P13 M 65 Glioblastoma—grade IV No No 12.8 7.0 54.5
P14 M 50 Anaplastic astrocytoma – grade III No No 13.8 1.8 13.4
P15 M 77 Glioblastoma – grade IV No No 20.2 1.2 5.8
P16 M 60 Glioblastoma – grade IV No – 40.5 5.4 13.3
P17 M 50 Glioblastoma – grade IV No No 78.6 9.1 11.5
P18 M 56 Glioblastoma – grade IV No No 13.5 1.1 8.0
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where S
amide,NAWMSamide,NAWM  is the average amide-
weighted signal in NAWM and 
NAWM
 is the standard 
deviation of S
amide
  in the NAWM. The percentage of vox-
els surpassing this threshold within the tumour ROI, as 
determined by dividing the numbers of voxels surpassing 
S
thresh
 within the tumour ROI by the total number of vox-
els covering the  T2-weighted FLAIR hyperintense tumour 
area, was calculated per slice and for the whole tumour 
for each patient. S represents the four different amide-
weighted contrasts calculated:  MTRasym and  LDamide, both 
calculated for  B1 is 2.5 and 3.8 µT.
Statistical analysis
Mixed effects linear regression models were fitted to deter-
mine whether there were significant effects of the fixed 
effects ROI and B1 on the CEST contrasts generated in 
the patient data  (MTRasym,  LDamide, and  LDNOE). The ROI 
factor contained two levels (NAWM and Tumour) and B1 
contained two levels (2.5 and 3.8 µT). To compare the 
different CEST contrasts for differentiating tumour tissue 





amide,NAWM + 2∗𝜎NAWM , Sthresh > Samide,NAWM + 2∗𝜎NAWM ,
A mixed effects linear regression model was also used 
to investigate whether there was a significant effect of con-
trast (two levels,  MTRasym and  LDamide) or B1 (two levels, 
2.5 and 3.8 µT) on the volume percentage of the tumour 
showing hyperintense amide-weighted signal.
Results
Group averaged z-spectra,  MTRasym and LD are plotted in 
Fig. 1. Group averaged values for all three CEST contrasts 
per ROI are stated in Table 2. For  MTRasym,  LDamide, and 
 LDNOE the mixed-effects linear regression showed a sig-
nificant effect of ROI (p < 0.05, Bonferroni corrected), indi-
cating significant differences found between NAWM and 
tumour tissue. Post-hoc paired t-tests illustrate that only 
for  MTRasym and  LDamide there are significant increases in 
tumour tissue versus NAWM (Table 2).The largest effect 
size for differentiating the whole tumour ROI and NAWM 
was found for  LDamide when using a saturation power of 3.8 
µT (Table 2).
Examples of the images generated by thresholding the 
 LDamide CEST maps generated for  B1 = 3.8 µT can be seen in 
Fig. 2. The hyperintense  LDamide voxels were heterogenously 
distributed across the tumours, as illustrated by Fig. 3. This 
figure illustrates that not necessarily all slices of the tumour 
Fig. 1  Z-spectra,  MTRasym and LD for NAWM and tumour ROI. The 
top row contains results for the  B1 power of 2.5 µT, the bottom row 
contains results for the  B1 power of 3.8 µT. Results are group aver-
aged (N = 18) and errorbars represent the standard deviation across 
the group. The Z-spectra in the left column are corrected for  B0 inho-
mogeneity, the  MTRasym and LD plots are additionally contrast  B1 
-corrected
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contain hyperintense  LDamide signal. For example, in P01 the 
three most proximal slices of the tumour show no hyperin-
tense  LDamide voxels. Figure 3 also illustrates that in 14 out 
of 18 patients the largest area of hyperintense  LDamide is not 
found in the slice with the largest tumour volume present. 
As an example, for P015 the slice with the largest amount 
of tumour voxels is slice 4, which contains no hyperintense 
 LDamide voxels.
On average, 17.9% ± 13.3% of the tumour vol-
ume showed hyperintense  LDamide, which was based 
on a calculated Sthresh of 0.031 ± 0.003 (N = 18). The 
hyperintense tumour volume percentages found for 
 LDamide,B1=2.5 µT,  MTRasym,B1=2.5 µT, and  MTRasym,B1=3.8 µT 
were 17.1% ± 12.4%, 12.7% ± 11.7%, and 13.1 ± 13.0%, 
respectively (boxplots in Fig. 4). Although on average the 
 LDamide contrasts lead to a larger volume showing hyperin-
tense signal in APT-weighted imaging, mixed-effects lin-
ear regressions did not show a significant effect of contrast 
Table 2  Averages and Cohen’s 
d effect size for CEST contrasts 
in non-enhancing glioma 
patients (N = 18)






B1 = 2.5 µT
MTRasym –0.006 ± 0.001 –0.002 ± 0.004  < 0.001* 1.1
LDamide 0.012 ± 0.001 0.015 ± 0.002  < 0.001* 1.6
LDNOE 0.017 ± 0.002 0.019 ± 0.003 0.200 0.3
B1 = 3.8 µT
MTRasym − 0.007 ± 0.002 − 0.002 ± 0.006  < 0.001* 1.0
LDamide 0.018 ± 0.002 0.023 ± 0.003  < 0.001* 1.7
LDNOE 0.025 ± 0.002 0.027 ± 0.005 0.083 0.4
Fig. 2  Examples of  LDamide images acquired for three different 
patients with a  B1 saturation power of 3.8 µT. Each of these patients 
has a different volume percentage of voxels with an increased 
 LDamide, which is stated below the patient number. The left colum 
shows the unthresholded  LDamide maps, followed by the map thres-
holded based on the NAWM  LDamide. The thresholded images are 
overlaid on the  T2-weighted FLAIR and axial (left), sagittal (top), and 
coronal slices (bottom) are presented
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on the volumes calculated (p = 0.045, which is larger than 
the Bonferroni corrected p-value threshold). Additionally, 
no significant effect of B1 power on the hyperintense vol-
ume percentage was found (mixed-effects linear regres-
sion, p = 0.795).
Discussion
We investigated APT-weighted CEST MRI in non-enhanc-
ing glioma and showed that Lorentzian difference analy-
ses are preferred in these type of tumours over the use of 
 MTRasym calculations since the largest effect size to differ-
entiate tumour from NAWM was found for  LDamide. Another 
important finding of this study is that, despite the majority 
of the non-enhancing glioma volume showing isointense 
signal amide-weighted CEST images, on average approxi-
mately 18% of the total volume of the  T2-FLAIR hyperin-
tense area showed hyperintensity on  LDamide images. The 
large area of isointense signal within these tumours is as 
expected, as earlier work in which non-enhancing glioma is 
included in patient populations has also found largely isoin-
tense APT-weighted CEST contrast [1, 4]. However, this 
work in which whole tumour coverage of non-enhancing 
glioma is done indicates that there are areas with hyper-
intense APT-weighted signal. This finding has two impor-
tant implications: (1) it illustrates the spatial heterogeneity 
Fig. 3  Volume percentage of tumour showing hyperintense  LDamide 
for the CEST acquisition with a  B1 saturation power of 3.8 µT. Each 
plot contains the volume percentages per slice containing tumour tis-
sue for one patient. Slice #1 is the most proximal slice. Note that each 
tumour has a different volume, reflected by different number of slices 
containing tumour tissue. The red bars indicate the slice with the larg-
est number of tumour voxels. For P15 this is slice 4, which does not 
contain hyperintense  LDamide voxels
Fig. 4  Boxplots of volume percentages showing hyperintense APT-
weighted signal for  MTRasym and  LDamide, for  B1 = 2.5 µT and 3.8 µT 
(N = 18). Although on average the  LDamide contrast leads to a slightly 
larger volume showing hyperintense signal in APT-weighted imag-
ing, mixed-effect ANOVA did not show a significant effect of con-
trast on the volumes calculated (p = 0.045). Additionally, no signifi-
cant effect of  B1 power on the hyperintense volume percentage was 
found (p = 0.795)
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of pathophysiology within non-enhancing glioma and (2) 
stresses the need for covering the whole tumour when 
acquiring APT-weighted CEST images.
In particular in light of the spatial heterogeneity in patho-
physiology and molecular signatures in non-enhancing 
glioma [5], the regions with hyperintense amide-weighted 
CEST signal may be areas where aggressive tumour tissue is 
present. This is an hypothesis strengthened by the potential 
sensitivity of APT-weighted CEST to protein build-up dur-
ing cell proliferation, as for instance shown by Togao et al.
[8] and Jiang et al.[23, 24] in a correlation between  MTRasym 
and the Ki-67 labelling index, a histopathological marker 
of cell proliferation, in patients with low- and high-grade 
glioma. In a pre-clinical study by Yan et al. both total cyto-
solic protein content and APT-weighted CEST signal were 
increased in glioma compared to healthy tissue [25]. These 
previous studies indicate the potential clinical relevance of 
increased APT-weighted signal in locating active tumour 
tissue, an aspect that is of importance in future work to target 
the most aggressive area of a tumour for accurate diagnosis.
Note that, in addition to cell proliferation, it is well known 
that other sources of CEST signal exist that can contribute to 
differences in signal between tumour and healthy tissue. We 
find that the use of a  B1 saturation power of 3.8 µT gave a 
stronger effect size than a  B1 of 2.5 µT for separating tumour 
from NAWM when using  LDamide. Note that, based on the 
theoretical optimal sensitivity of CEST MRI to amide pro-
tons when using a lower  B1 saturation power (~ 1 µT [10]), 
this finding corroborates that there must be other sources (in 
part) responsible for differentiation of glioma and NAWM 
in our study. Based on previous studies, these other sources 
include the following: (i) a non-linear relationship between 
 B1 saturation power and the ratio of  T1-water relaxation 
times and overall water content, with the latter parameters 
 (T1 of water and water content) likely to be increased in 
the tumour compared to NAWM [25], (ii) a decrease in 
magnetisation transfer from semisolid macromolecules in 
tumour compared NAWM [26], in particular, if increased  B1 
saturation power increases magnetisation transfer effects in 
NAWM in a stronger manner than in the tumour, (iii) con-
tributions to the CEST signal from fast exchanging amine 
protons resonating around 2–3 ppm because of the relatively 
high  B1 saturation pulse used here [27].
Although our results indicate that differences in APT-
weighted CEST are found in non-enhancing glioma as 
well, it is thus clear that the origin of increased amide-
weighted CEST contrasts in non-enhancing glioma is still 
to be investigated. This should first be done with an exten-
sive MR imaging protocol, including quantification of  T1, 
high-resolution structural imaging (pre- & post-contrast 
 T1,  T2-weighted FLAIR), and a CEST acquisition that 
allows for separation of CEST signal from amide protons, 
NOE and MT effects. Such a CEST acquisition could be 
designed to be as selective to amide protons as possible, 
for instance as done by Zaiss et al.[26] at ultrahigh field 
(9.4 T), with low  B1 saturation power and the acquisition 
of a full Z-spectrum such that multi-pool Lorentzian fitting 
can be used to separate different CEST signal sources. To 
assess the extent to which amide protons are contributing to 
the differences in APT-weighted CEST imaging should be 
followed by targeted biopsies of tumour tissue for ex vivo 
analysis of the local environment with proteomics analysis 
[25, 28], rather than cell proliferation indices, that at mini-
mum include measurement of cytosolic protein content and 
potentially further investigate specific mobile proteins and 
semisolid macromolecules contributing to the CEST signal.
Second, if the hyperintensities in amide-weighted CEST 
MRI are highlighting more aggressive tumour tissue it is 
important to not miss these regions when imaging non-
enhancing glioma, stressing the need for having a CEST 
acquisition that covers the whole tumour volume. Note that 
although this may seem to go against the finding of Sakata 
et al. [2], who showed that for differentiation of low- and 
high-grade tumours single slice acquisition worked equally 
well as multi-slice acquisitions, the example of P15 in this 
work illustrates that hyperintense APT-weighted signal may 
be missed if a single slice is imaged. However, note that 
the work by Sakata et al. was conducted before the updated 
WHO tumour classification of 2016 in which the molecu-
lar diagnosis became important for grading. Moreover, 
advances in image acquisition for CEST MRI have enabled 
rapid measurement of full Z-spectra for multi-slice volumes 
in clinically feasible scan time, e.g. [10, 11]. Therefore, it 
is recommended in future work investigating CEST MRI 
for imaging diagnostics in non-enhancing glioma to use 
full tumour coverage as much as possible. This would for 
instance aid future research investigating whether amide-
weighted CEST MRI can be used to direct biopsies for accu-
rate non-enhancing glioma diagnosis in light of the recent 
WHO classification or improve the use of CEST MRI for 
differentiation of tumour progression and radiation necrosis 
in treatment follow-up in glioma patients.
Note that here we found that  LDamide results in a larger 
effect size than  MTRasym to differentiate non-enhancing gli-
oma tissue from NAWM, which may be caused by finding 
no significant difference for  LDNOE between non-enhancing 
glioma and NAWM. This latter finding may be as expected, 
as previous studies on high-grade, enhancing gliomas show-
ing that  LDNOE correlated with prognosis [13, 14] and grad-
ing [15], all done at 7 T, show that stronger decreases in 
 LDNOE compared to NAWM correlate to worse prognosis/
grade in enhancing glioma, with limited changes in  LDNOE 
for tumours with better outcome. Moreover, at 3 T and in 11 
high-grade glioma patients, Heo et al.[29] report only slight 
hypointensity in  LDNOE in tumour tissue. Extrapolating these 
results to this study in which we only include non-enhancing 
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glioma may suggest that not finding a significant  LDNOE 
effect in the current study is plausible. Note that, as a con-
sequence of finding limited effects of  LDNOE, the largest 
effect size in separating NAWM from non-enhancing glioma 
was found for  LDamide in the current study, with  MTRasym 
being affected by both amide- and NOE-weighted signals 
within the tumour and hence the noise in  MTRasym being 
affected by CEST signal at both 3.5 and − 3.5 ppm, illus-
trated by the ratio of the standard deviations compared to the 
group averaged values being larger for  MTRasym (Table 2). 
Additionally, using  MTRasym there was a trend to find 
smaller hyperintense tumour volumes than using  LDamide 
maps. This suggests that with using  MTRasym regions of 
increased amide-weighted signal within the tumour may be 
missed. Although we do acknowledge that these findings 
at this stage are specific to the set-up as used here and an 
increased SNR for  MTRasym APT-weighted images, as can 
be obtained by increasing the number of acquisitions on and 
around ± 3.5 ppm [30], can lead to increased sensitivity to 
areas of increased APT-weighted signal for asymmetry anal-
ysis. Future work is required to further investigate whether 
this finding can be confirmed for non-enhancing glioma with 
a set-up optimised for  MTRasym analysis.
Limitations
The number of included patients is likely too small for thor-
ough investigation of using amide-weighted imaging for 
classification of non-enhancing glioma. Analyses to inves-
tigate differences between the three different tumour types, 
as well as IDH-mutation (N = 12) vs IDH-wildtype (N = 6) 
tumours were performed but resulted in no significant dif-
ferences for the CEST contrasts as well as the size of the 
hyperintense volumes (results in Supplementary informa-
tion). However, note that Paech et al. [13] and Jiang et al. 
[9] showed that amide proton weighted CEST signal has 
predictive value in assessing IDH mutation status, allowing 
for differentiation of low- and high-grade gliomas based on 
CEST imaging alone, potentially even within non-enhancing 
glioma solely. Future work is required to corroborate those 
findings.
B0-correction was carried out with the CEST data itself, 
rather than acquiring an external map with a low  B1 satu-
ration power [31]. This means that the  B0 correction here 
may be affected by hydroxyl protons, resonating close to the 
water peak (~ 0.9 ppm [12]) causing potential inaccuracies. 
However, in the  B0-correction performed points further than 
1 ppm away from the water peak were excluded and with 
visual inspection of the Z-spectra for  B1 is 2.5 μT (Fig. 2) 
it is not likely that  B0-correction is affected by widening 
of the peak around the OH-peak. Note that the wider peak 
at the largest  B1 used suggests that  B0-correction for this 
acquisition may be contaminated by hydroxyl protons reso-
nating near 0.9 ppm. This effectively means that the  B0- cor-
rection at high  B1 saturation power is overestimated and a 
larger shift towards the upfield frequencies is applied than 
strictly required. Effectively this would lead to underestima-
tion of the APT-weighted signal at 3.5 ppm. The true extent 
to which this will affect the results in this work is hard to 
gauge. It is recommended in future work to use a separate 
acquisition with low  B1 saturation power for  B0-correction.
A steady-state CEST sequence is used in this work, as 
at the time of initiating this study it was deemed the most 
appropriate for rapid acquisition of whole tumour volume at 
our institute. However, there are alternatives now with long 
saturation blocks prior to image read-out that may result in 
higher signal-to-noise ratios for the CEST contrast images 
[11]. Future work, therefore, includes the investigation of 
heterogeneity in APT-weighted CEST signal in non-enhanc-
ing glioma with longer pre-saturation blocks.
Conclusions
This study illustrates that 3D pulsed CEST imaging allows 
for measuring heterogeneity in amide-weighted CEST sig-
nal in non-enhancing glioma. Based on the results in this 
study we recommend to use CEST acquisitions that cover 
the whole tumour volume for assessment of non-enhancing 
glioma, to not miss areas of hyperintense APT-weighted sig-
nal which may be small within these tumours. Future work 
includes investigation of the cause for increased  LDamide, 
which is a step towards the application of APT-weighted 
CEST MRI for accurate diagnosis and treatment follow-up 
in light of the new molecular classification of non-enhancing 
glioma.
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